206650.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:30):

Stats
Today's Volume	458 031
Average Volume	432 159
Market Cap	463.34B
EPS	KRW-85.00 ( 2023-09-30 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	-107.13
ATR14	KRW22.58 (0.18%)

Volume Correlation

Long: -0.01 (neutral)

Short: 0.56 (weak)

Signal:(48.665) Neutral

EuBiologics Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

EuBiologics Co., Ltd. Correlation - Currency/Commodity

0.62
( weak )

0.65
( weak )

0.31
( neutral )

0.55
( weak )

-0.75
( moderate negative )

0.20
( neutral )

EuBiologics Co., Ltd. Financials

Annual	2023
Revenue:	KRW69.37B
Gross Profit:	KRW32.66B (47.08 %)
EPS:	KRW-380.79

Q4	2023
Revenue:	KRW26.89B
Gross Profit:	KRW13.44B (49.99 %)
EPS:	KRW-348.63

Q3	2023
Revenue:	KRW11.43B
Gross Profit:	KRW3.32B (29.00 %)
EPS:	KRW-85.10

Q2	2023
Revenue:	KRW16.65B
Gross Profit:	KRW8.55B (51.38 %)
EPS:	KRW55.92

Financial Reports:

No articles found.

EuBiologics Co., Ltd.

EuBiologics Co., Ltd., a biopharmaceutical company, develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine. The company also provides customized services for mammalian cell and microbial cell derived biopharmaceuticals in accordance with the clients' project stages, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. It specializes in manufacturing a range of mammalian cell and microbial cell derived biopharmaceuticals, including recombinant biological products and antibody therapeutics. In addition, the company offers process, formulation, and analytical method development, as well as licensing consulting services; and contract testing services that include lot release, stability, raw material, and method validation testing services. The company was founded in 2010 and is based in Seoul, South Korea.